Cancer Research Technology (CRT) has purchased 2,000 Maybridge fragments as the foundation of its fragment screening library.
The Maybridge fragment collection will be used in CRT's discovery laboratories in London and Cambridge for fragment-based screening, to accelerate the identification of drug leads against cancer targets.
The availability of related building blocks featuring the same fragments from Maybridge stock eases the rapid construction of a library around chosen core fragments for hit-to-lead work and further optimisation.
The Maybridge fragment collection is a convenient source of pre-selected, high-quality building blocks, a distillation of Maybridge's combined expertise in heterocyclic compound design.
Over 30,000 compounds have been assembled to form a pool from which researchers can build their own customised fragment libraries.
This collection has been selected for purity, low molecular weight and absence of inappropriate functionality.
All compounds are easily resupplied and available custom-weighed in milligrams or micromoles.
Many of the Maybridge fragments are fully 'Rule of Three'-compliant, meaning that the physicochemical properties of these fragments are optimal; therefore increasing the probability of future hits.
